Copenhagen, 2011-12-01 11:28 CET (GLOBE NEWSWIRE) -- Company Announcement
No. 24/2011
Copenhagen, 1 December 2011 - Following Company Announcement no. 19/2011 of 17 November 2011, Zealand Pharma (ZEAL.CO) hereby announces that the final number of warrants issued by the company’s Board of Directors at the board meeting of 17 November 2011, according to the authority provided by Section 8.1 of the Articles of Association, amounts to 227,085 for the subscription of shares of up to nominally DKK 227,085.
For a further description of the issued warrants, reference is made to Company Announcement no. 19/2011.
The amendment of the Articles of Association entailed by the issue of warrants has today been registered with the Danish Commerce and Companies Agency. The new Articles of Association for Zealand Pharma are attached to this announcement and are also available on the company’s website; www.zealandpharma.com.
For further information, please contact:
David Horn Solomon, President and Chief Executive Officer
Tel: +45 2220 6300
Hanne Leth Hillman, Vice President for IR & Corporate Communication
Tel: +45 5060 3689
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing clinical pipeline of innovative peptide based drugs. The company's lead product is Lyxumia® 1) (lixisenatide), a once-daily GLP-1 agonist for the treatment of Type-2 diabetes, discovered by Zealand Pharma and licensed to Sanofi. In October 2011, Sanofi submitted an MAA for Lyxumia® (lixisenatide) in Europe and submission for regulatory approval in the United States is planned for Q4 2012. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity, and a licence agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the treatment of chemotherapy- and radiotherapy- induced diarrhea.
Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs, and all drug candidates in its pipeline have been identified through the company's own drug discovery activities. Zealand Pharma's products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com.
Note 1): Lyxumia® is the intended trademark of lixisenatide.
